瑞典的一项研究发现, 一型糖尿病患者面临着两倍以上的支架并发症风险, Type 1 diabetes patients face over double the risk of stent complications, especially in the first month, a Swedish study finds.

瑞典在2025年11月27日《糖尿病护理》上公布的一项大型研究发现,糖尿病患者,特别是1型糖尿病患者,在接受药物浸泡剂后,面临更大程度的并发症风险。 A large Swedish study published in Diabetes Care on November 27, 2025, finds that people with diabetes, especially type 1, face a significantly higher risk of complications after receiving drug-eluting stents. 2010年至2020年期间,研究人员对160,000多名患者进行了分析,发现1型糖尿病患者患动脉再收缩或血栓等疾病的风险比非糖尿病患者高出一倍以上,在第一个月风险最高。 Analyzing over 160,000 patients from 2010 to 2020, researchers found type 1 diabetes patients had more than double the risk of issues like artery re-narrowing or blood clots compared to non-diabetic patients, with the highest risk in the first month. 即使在6个月后,糖尿病患者的风险仍然较高,这突出表明需要量身定制的护理。 The risk remained elevated for diabetic patients even after six months, highlighting the need for tailored care.